Pemetrexed Fresenius Kabi 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
II/0035/G 
This was an application for a group of variations. 
18/01/2024 
SmPC 
B.II.b.4.z - Change in the batch size (including batch 
size ranges) of the finished product - Other variation 
B.II.e.1.b.2 - Change in immediate packaging of the 
finished product - Change in type/addition of a new 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
container - Sterile medicinal products and 
biological/immunological medicinal products 
B.II.e.4.c - Change in shape or dimensions of the 
container or closure (immediate packaging) - Sterile 
medicinal products 
IA/0034 
A.5.b - Administrative change - Change in the name 
24/05/2023 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IB/0033/G 
This was an application for a group of variations. 
16/12/2022 
n/a 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.a.4.b - Change to in-process tests or limits 
applied during the manufacture of the AS - Addition 
of a new in-process test and limits 
B.I.a.4.a - Change to in-process tests or limits 
applied during the manufacture of the AS - 
Tightening of in-process limits 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
B.I.a.4.b - Change to in-process tests or limits 
applied during the manufacture of the AS - Addition 
of a new in-process test and limits 
B.I.b.2.c - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure for a reagent, which 
Page 2/11 
 
 
 
 
 
 
 
 
 
 
 
 
does not have a significant effect on the overall 
quality of the AS 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
IB/0032 
C.I.z - Changes (Safety/Efficacy) of Human and 
26/07/2022 
09/08/2023 
SmPC and PL 
To update sections 4.4 and 4.6 of the SmPC based on the 
Veterinary Medicinal Products - Other variation 
recommended wording provided in the "Report from the 
CMD(h) meeting held on 20-21 July 2021" concerning 
duration of contraception following the end of treatment 
with a genotoxic drug. The PL has been updated 
accordingly. 
IB/0031/G 
This was an application for a group of variations. 
14/01/2022 
n/a 
B.II.e.z - Change in container closure system of the 
Finished Product - Other variation 
B.II.e.z - Change in container closure system of the 
Finished Product - Other variation 
Page 3/11 
 
 
 
 
 
 
 
 
 
 
B.II.e.2.c - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Deletion of a non-significant 
specification parameter (e.g. deletion of an obsolete 
parameter) 
PSUSA/2330/
Periodic Safety Update EU Single assessment - 
30/09/2021 
n/a 
PRAC Recommendation - maintenance 
202102 
pemetrexed 
IB/0030/G 
This was an application for a group of variations. 
26/09/2021 
n/a 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
IA/0029 
B.II.b.2.a - Change to importer, batch release 
01/06/2021 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
Page 4/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0027 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
31/05/2021 
21/06/2022 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IAIN/0026/G 
This was an application for a group of variations. 
26/04/2021 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
R/0023 
Renewal of the marketing authorisation. 
25/02/2021 
21/04/2021 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Pemetrexed Fresenius Kabi in the approved indication 
remains favourable and therefore recommended the 
renewal of the marketing authorisation with unlimited 
validity. 
IAIN/0024/G 
This was an application for a group of variations. 
20/01/2021 
21/04/2021 
PL 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0022/G 
This was an application for a group of variations. 
20/11/2020 
21/04/2021 
SmPC, Annex 
II, Labelling 
Page 5/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
and PL 
A.7 - Administrative change - Deletion of 
manufacturing sites 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0020 
B.I.a.2.e - Changes in the manufacturing process of 
28/10/2020 
n/a 
the AS - Minor change to the restricted part of an 
ASMF 
IA/0021 
B.I.b.1.d - Change in the specification parameters 
19/10/2020 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
IAIN/0019/G 
This was an application for a group of variations. 
06/07/2020 
21/04/2021 
Annex II and 
PL 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
Page 6/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0018 
B.II.b.2.a - Change to importer, batch release 
24/06/2020 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IB/0017 
C.I.2.a - Change in the SPC, Labelling or PL of a 
30/05/2020 
21/04/2021 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
X/0009 
Annex I_2.(d) Change or addition of a new 
14/11/2019 
11/02/2020 
SmPC, 
pharmaceutical form 
Labelling and 
PL 
IB/0016/G 
This was an application for a group of variations. 
18/12/2019 
n/a 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.d.1.c - Stability of AS - Change in the re-test 
period/storage period or storage conditions - Change 
to an approved stability protocol 
Page 7/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0015/G 
This was an application for a group of variations. 
03/10/2019 
11/02/2020 
Annex II and 
PL 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0014 
C.I.3.a - Change(s) in the SPC, Labelling or PL 
26/04/2019 
11/02/2020 
SmPC and PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Implementation of 
wording agreed by the competent authority 
IAIN/0013 
B.II.b.2.c.1 - Change to importer, batch release 
13/03/2019 
11/02/2020 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IA/0012 
B.II.b.2.a - Change to importer, batch release 
01/02/2019 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IA/0011 
B.II.b.2.a - Change to importer, batch release 
14/01/2019 
n/a 
Page 8/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IB/0010 
B.I.b.2.e - Change in test procedure for AS or 
20/11/2018 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IA/0008/G 
This was an application for a group of variations. 
03/10/2018 
n/a 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
T/0007 
Transfer of Marketing Authorisation 
04/06/2018 
06/07/2018 
SmPC, 
Labelling and 
PL 
Page 9/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0006 
C.I.z - Changes (Safety/Efficacy) of Human and 
13/04/2018 
06/07/2018 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IB/0005 
B.II.b.4.a - Change in the batch size (including batch 
18/01/2018 
n/a 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
IB/0004/G 
This was an application for a group of variations. 
14/08/2017 
08/05/2018 
SmPC 
B.II.b.3.z - Change in the manufacturing process of 
the finished or intermediate product - Other variation 
B.II.f.1.b.3 - Stability of FP - Extension of the shelf 
life of the finished product - After dilution or 
reconstitution (supported by real time data) 
II/0002 
B.I.z - Quality change - Active substance - Other 
06/07/2017 
n/a 
variation 
IB/0003 
C.I.2.a - Change in the SPC, Labelling or PL of a 
22/05/2017 
08/05/2018 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0001/G 
This was an application for a group of variations. 
18/10/2016 
n/a 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
Page 10/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
batch control/testing takes place 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
B.I.d.1.c - Stability of AS - Change in the re-test 
period/storage period or storage conditions - Change 
to an approved stability protocol 
B.I.a.3.b - Change in batch size (including batch size 
ranges) of AS or intermediate - Downscaling down to 
10-fold 
Page 11/11 
 
 
 
 
 
 
 
